Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Authors
Théoleyre, SKwan Tat, S
Vusio, P
Blanchard, F
Gallagher, John T
Ricard-Blum, S
Fortun, Y
Padrines, M
Rédini, F
Heymann, D
Affiliation
INSERM, ERI 7, Nantes, F-44035, France.Issue Date
2006-08-25
Metadata
Show full item recordAbstract
Osteoprotegerin (OPG) is a decoy receptor for receptor activator of nuclear factor kappaB ligand (RANKL), a key inducer of osteoclastogenesis via its receptor RANK. We previously showed that RANK, RANKL, and OPG are able to form a tertiary complex and that OPG must be also considered as a direct effector of osteoclast functions. As OPG contains a heparin-binding domain, the present study investigated the interactions between OPG and glycosaminoglycans (GAGs) by surface plasmon resonance and their involvement in the OPG functions. Kinetic data demonstrated that OPG binds to heparin with a high-affinity (KD: 0.28 nM) and that the pre-incubation of OPG with heparin inhibits in a dose-dependent manner the OPG binding to the complex RANK-RANKL. GAGs from different structure/origin (heparan sulfate, dermatan sulfate, and chondroitin sulfate) exert similar activity on OPG binding. The contribution of the sulfation pattern and the size of the oligosaccharide were determined in this inhibitory mechanism. The results demonstrated that sulfation is essential in the OPG-blocking function of GAGs since a totally desulfated heparin loses its capacity to bind and to block OPG binding to RANKL. Moreover, a decasaccharide is the minimal structure that totally inhibits the OPG binding to the complex RANK-RANKL. Western blot analysis performed in 293 cells surexpressing RANKL revealed that the pre-incubation of OPG with these GAGs strongly inhibits the OPG-induced decrease of membrane RANKL half-life. These data support an essential function of the related glycosaminoglycans heparin and heparan sulfate in the activity of the triad RANK-RANKL-OPG.Citation
Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. 2006, 347 (2):460-7 Biochem. Biophys. Res. Commun.Journal
Biochemical and Biophysical Research CommunicationsDOI
10.1016/j.bbrc.2006.06.120PubMed ID
16828054Type
ArticleLanguage
enISSN
0006-291Xae974a485f413a2113503eed53cd6c53
10.1016/j.bbrc.2006.06.120
Scopus Count
Collections
Related articles
- Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
- Authors: Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H
- Issue date: 2000 Sep 7
- Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
- Authors: Ikeda T, Utsuyama M, Hirokawa K
- Issue date: 2001 Aug
- Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
- Authors: Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE
- Issue date: 2002
- Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
- Authors: Lu HK, Chen YL, Chang HC, Li CL, Kuo MY
- Issue date: 2006 Aug
- Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
- Authors: Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D
- Issue date: 2006 Mar